NCT05882708 is a Phase 4 clinical trial of Ivabradine in Sepsis, sponsored by Second Affiliated Hospital of Guangzhou Medical University.

Who is sponsoring NCT05882708?

NCT05882708 is sponsored by Second Affiliated Hospital of Guangzhou Medical University.

What drugs are being tested in NCT05882708?

Interventions in NCT05882708: Ivabradine.

What condition does NCT05882708 study?

NCT05882708 studies Sepsis, Ivabradine, Hemodynamics, Heart Rate Control.

Is NCT05882708 still recruiting?

NCT05882708 is currently status unknown. Last updated 29 January 2024.

Last reviewed 2024-01-29 · How we verify

NCT05882708

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis

Status unknown Phase 4 Last updated 29 January 2024

What this trial tests

Phase 4 trial testing Ivabradine in Sepsis in 172 participants. Status unknown.

Timeline

1 June 2023

Primary endpoint
31 December 2024

31 March 2025

Quick facts

Lead sponsor	Second Affiliated Hospital of Guangzhou Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	172
Start date	1 June 2023
Primary completion	31 December 2024
Estimated completion	31 March 2025
Sites	1 location across China

Drugs / interventions tested

Ivabradine (IVABRADINE) — full drug profile →

Conditions studied

Sepsis — all drugs for Sepsis →
Ivabradine — all drugs for Ivabradine →
Hemodynamics — all drugs for Hemodynamics →
Heart Rate Control — all drugs for Heart Rate Control →

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Who can join

18 and older, any sex, with Sepsis or Ivabradine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sepsis, a life-threatening syndrome, is often accompanied by tachycardia in spite of adequate volume resuscitation to correct hypovolemia and vasopressor medication to correct hypotension. Recently, relevant studies have shown that sustained tachycardia in sepsis was also related to high mortality, and appropriate control of heart rate could improve prognosis. Ivabradine reduces heart rate directly without a negative inotropic effect through inhibition of the If ionic current，which is absent from the traditional rate control drug (beta-blockers). This is a prospective, multicenter, randomized, open label study designed to compare ivabradine with placebo on the difference of heart rate and haemodynamics in patients with sepsis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of heart rate control with ivabradine on hemodynamic in patients with sepsis: study protocol for a prospective, multicenter, randomized controlled trial.
Zheng J, Wen D, Pan Z, Chen X, et al · · 2024 · cited 2× · PMID 39443954 · DOI 10.1186/s13063-024-08560-5

Verify or expand the search:

Other trials of Ivabradine

Trials testing the same drug.

NCT07268170 — Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease · Phase 2, PHASE3 · enrolling by invitation
NCT06312891 — Value of Heart Rate Lowering Therapy in Acute Myocarditis · unknown
NCT06305806 — RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) · Phase 2 · completed
NCT06670690 — Comparison Between Atenolol,Propnalol and Ivabradine · NA · completed
NCT05481177 — Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort · Phase 4 · unknown

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other Second Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

NCT06966830 — Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus · not yet recruiting
NCT06936683 — Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study） · not yet recruiting
NCT07374328 — Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus · Phase 1, PHASE2 · recruiting
NCT06904183 — Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT · Phase 2 · recruiting
NCT06904196 — Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05882708 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Guangzhou Medical University
Last refreshed: 29 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05882708.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing